| Q39287807 | A new Nav1.7 sodium channel mutation I234T in a child with severe pain |
| Q34576217 | A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers |
| Q42216090 | A residue in the transmembrane segment 6 of domain I in insect and mammalian sodium channels regulate differential sensitivities to pyrethroid insecticides |
| Q38040330 | Advances in targeting voltage-gated sodium channels with small molecules |
| Q37618837 | An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature |
| Q39152198 | Between fire and ice: refractory hypothermia and warmth-induced pain in inherited erythromelalgia. |
| Q55209407 | Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. |
| Q28542981 | Carbamazepine potentiates the effectiveness of morphine in a rodent model of neuropathic pain |
| Q54979414 | Co-expression of β Subunits with the Voltage-Gated Sodium Channel NaV1.7: the Importance of Subunit Association and Phosphorylation and Their Effects on Channel Pharmacology and Biophysics. |
| Q39155847 | Complex management of a patient with refractory primary erythromelalgia lacking a SCN9A mutation |
| Q100761872 | Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromes |
| Q64892486 | Current pain management strategies for patients with erythromelalgia: a critical review. |
| Q36633107 | Development of a Rapid Throughput Assay for Identification of hNav1.7 Antagonist Using Unique Efficacious Sodium Channel Agonist, Antillatoxin |
| Q89502829 | Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy |
| Q52746542 | Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. |
| Q38292223 | Expert opinion on emerging drugs: chronic low back pain |
| Q41210428 | Extending the clinical spectrum of pain channelopathies |
| Q34309236 | Gain-of-function Nav1.8 mutations in painful neuropathy. |
| Q37162329 | Genomics of pain in osteoarthritis. |
| Q36142473 | Guest editorial: Opportunities in rehabilitation research. |
| Q38030606 | Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. |
| Q48062762 | Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile |
| Q35275248 | Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide |
| Q88919604 | Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain |
| Q90089706 | Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7. |
| Q34402820 | Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. |
| Q33875626 | Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders |
| Q36290427 | Network topology of NaV1.7 mutations in sodium channel-related painful disorders. |
| Q38042001 | Neurological perspectives on voltage-gated sodium channels. |
| Q44688179 | Neuropathic pain in children. |
| Q57255327 | Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A back-translational study of oxcarbazepine |
| Q47979740 | Nonlinear effects of hyperpolarizing shifts in activation of mutant Nav1.7 channels on resting membrane potential |
| Q36329924 | Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy |
| Q37943756 | Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations |
| Q43323322 | Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons |
| Q36110592 | Pharmacogenetics of analgesic drugs |
| Q84964612 | Polymorphisms in ion channel genes: emerging roles in pain |
| Q26784432 | Primary erythromelalgia: a review |
| Q47977892 | Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T. |
| Q37950230 | Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation |
| Q38260278 | Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. |
| Q37681340 | Sodium channelopathies and pain |
| Q47959907 | Sodium channels in pain disorders: pathophysiology and prospects for treatment |
| Q37992862 | Sodium channels, the electrogenisome and the electrogenistat: lessons and questions from the clinic |
| Q28728868 | Splice variants of Na(V)1.7 sodium channels have distinct β subunit-dependent biophysical properties |
| Q101038915 | Status of peripheral sodium channel blockers for non-addictive pain treatment |
| Q42211742 | Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. |
| Q38626606 | Targeting voltage-gated calcium channels in neurological and psychiatric diseases |
| Q36258703 | The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development |
| Q36139482 | The Biophysical Basis Underlying Gating Changes in the p.V1316A Mutant Nav1.7 Channel and the Molecular Pathogenesis of Inherited Erythromelalgia |
| Q38066723 | The Na(V)1.7 sodium channel: from molecule to man. |
| Q26744730 | Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery |
| Q91658224 | Translational issues in precision medicine in neuropathic pain |
| Q38239812 | Translational pain research: Lessons from genetics and genomics |
| Q92459370 | Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments |
| Q51602622 | Understanding chronic inflammatory and neuropathic pain. |
| Q37714086 | Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. |
| Q38997463 | What are the treatment options for paroxysmal extreme pain disorder? |
| Q58611367 | [EXPRESS] A novel gain-of-function Na1.7 mutation in a carbamazepine-responsive patient with adult-onset painful peripheral neuropathy |
| Q54645891 | [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment]. |
| Q53067627 | [Pain and analgesia : Mutations of voltage-gated sodium channels]. |